Literature DB >> 20549703

Glucocorticoids are not always deleterious for bone.

Antoon H J M van Lierop1, Neveen A T Hamdy, Socrates E Papapoulos.   

Abstract

A 23-year-old man with the rare sclerosing bone disorder van Buchem disease presented with progressively worsening headaches that eventually became persistent and associated with papilledema. Increased intracranial pressure was diagnosed, and the patient had a ventriculoperitoneal drain inserted as well as simultaneously receiving treatment with prednisone. Before starting treatment, there was biochemical evidence for increased bone turnover and for steady increases in bone mineral density (BMD) at the spine and total hip despite the patient having reached his peak height of 197 cm at the age of 19 years. Treatment with prednisone for 2 years resulted in biochemical and histologic suppression of bone formation as well as of bone resorption and arrest of further bone accumulation. Our data suggest that glucocorticoids (GCs) may represent an attractive alternative to the high-risk surgical approaches used in the management of patients with progressive sclerosing bone disorders. Our findings also suggest that whereas sclerostin may not be required for the action of GCs on bone formation, it may well be important for the action of GCs on bone resorption. The exact mechanism by which sclerostin may be involved in the regulation of bone resorption is as yet to be explored.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549703     DOI: 10.1002/jbmr.151

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

Review 1.  TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.

Authors:  Elena Gallo MacFarlane; Julia Haupt; Harry C Dietz; Eileen M Shore
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 2.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

Review 3.  Glucocorticoid-induced osteoporosis: who to treat with what agent?

Authors:  René Rizzoli; Emmanuel Biver
Journal:  Nat Rev Rheumatol       Date:  2014-11-11       Impact factor: 20.543

4.  Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

Authors:  A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2012-07-27       Impact factor: 5.958

5.  GLUCOCORTICOID EXCESS IN BONE AND MUSCLE.

Authors:  Amy Y Sato; Munro Peacock; Teresita Bellido
Journal:  Clin Rev Bone Miner Metab       Date:  2018-02-05

6.  Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.

Authors:  Amy Y Sato; Meloney Cregor; Jesus Delgado-Calle; Keith W Condon; Matthew R Allen; Munro Peacock; Lilian I Plotkin; Teresita Bellido
Journal:  J Bone Miner Res       Date:  2016-06-05       Impact factor: 6.741

Review 7.  From disease to treatment: from rare skeletal disorders to treatments for osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Endocrine       Date:  2016-02-18       Impact factor: 3.633

Review 8.  Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management.

Authors:  Celia L Gregson; Sarah A Hardcastle; Cyrus Cooper; Jonathan H Tobias
Journal:  Rheumatology (Oxford)       Date:  2013-02-27       Impact factor: 7.580

9.  Van Buchem disease: First case report in Taiwan.

Authors:  Shang-Fu Hsu; Chen-Chun Lin
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Sost Haploinsufficiency Provokes Peracute Lethal Cardiac Tamponade without Rescuing the Osteopenia in a Mouse Model of Excess Glucocorticoids.

Authors:  Behzad Javaheri; Eleanor Herbert; Mark Hopkinson; Ahmed Al-Jazzar; Andrew A Pitsillides
Journal:  Am J Pathol       Date:  2019-01-19       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.